Pulmatrix Inc
Research Pulmatrix Inc (PULM) on Bullrun: market cap USD 5.84M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPULM
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 5.84M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 1.17M
- Free cash flow-USD 1.07M
Valuation Snapshot
latest market cap is USD 5.84M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 5.16M | -USD 5.43M | n/a | -1.41 | USD 4.09M | n/a | USD 3.81M |
| FY2024 | USD 7.81M | -USD 9.56M | -USD 11.11M | n/a | -2.62 | USD 9.52M | USD 0 | USD 8.95M |
| FY2023 | USD 7.30M | -USD 14.12M | -USD 16.66M | n/a | -3.87 | USD 19.17M | USD 8.76M | USD 18.00M |
| FY2022 | USD 6.07M | -USD 18.84M | -USD 19.44M | n/a | -5.46 | USD 35.63M | USD 1.70M | USD 31.11M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 5.84M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 8.14M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 25.49M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 6.79M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 14.12M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 28.22M | n/a | n/a | n/a |
About Pulmatrix Inc
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Pulmatrix Inc's market cap?
Pulmatrix Inc's market capitalization is USD 5.84M.
What does Pulmatrix Inc do?
Pulmatrix, Inc., a biopharmaceutical company, focused on development of novel inhaled therapeutic products to prevent and treat migraine and respiratory diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.